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Abstract:
In the liver, citrate is a key metabolic intermediate involved in the regulation of glycolysis and lipid synthesis and reduced expression of the hepatic citrate SLC13A5 transporter has been shown to improve metabolic outcomes in various animal models. Although inhibition of hepatic extracellular citrate uptake through SLC13A5 has been suggested as a potential therapeutic approach for Type-2 diabetes and/or fatty liver disease, so far, only a few SLC13A5 inhibitors have been identified. Moreover, their mechanism of action still remains unclear, potentially limiting their utility for in vivo proof-of-concept studies. In this study, we characterized the pharmacology of the recently identified hydroxysuccinic acid SLC13A5
inhibitors, PF-06649298 and PF-06761281, using a combination of 14 C-citrate uptake, a membrane potential assay and electrophysiology. In contrast to their previously proposed mechanism of action, our data suggest that both PF-06649298 and PF-06761281 are allosteric, state-dependent SLC13A5 inhibitors, with low-affinity substrate activity in the absence of citrate. As allosteric state-dependent modulators, the inhibitory potency of both compounds is highly dependent on the ambient citrate concentration and our detailed mechanism of action studies therefore, may be of value in interpreting the in vivo effects of these compounds. SLC13A5, also called NaCT or INDY, is a member of the sodium-dependent dicarboxylate/sulphate cotransporter gene family that preferentially transports the tricarboxylate citrate (Bergeron et al., 2013; Markovich, 2012; Markovich et al., 2004; Pajor, 2014) . In human, SLC13A5 is mostly expressed in the liver, brain and salivary glands, where it is responsible for the uptake of circulating citrate, a key regulatory metabolic intermediate that facilitates the integration of the glycolysis and lipid synthesis pathways (Willmes et al., 2013) . Several studies have shown that SLC13A5 may be an important regulator of cellular metabolism. For example, SLC13A5 gene expression has recently been reported to be regulated by metabolic state-dependent pathways, through changes in hormonal and/or nutritional status (Neuschafer-Rube et al., 2014) . Moreover, SLC13A5 was also shown to be a transcriptional target of the Pregnane X receptor (PXR), that plays a key role in the control of energy homeostasis, through for instance the regulation of lipogenic enzymes (Li et al., 2015) . PXR activation by rifampicin increases lipid accumulation in hepatocytes whereas lipid content in HepG2 cells was significantly reduced following SLC13A5 knockdown (Li et al., 2015) . Additional genetic studies have identified a key role of SLC13A5 in metabolic disorders and liver fat deposition. Deletion of SLC13A5 in mice results in protection from adiposity and insulin resistance associated with excess caloric intake and aging (Birkenfeld et al., 2011) . Similarly, selective knockdown of the citrate transporter in the rat liver led to a significant reduction of liver fat content and plasma triglycerides, and hepatic insulin sensitivity was overall improved (Pesta et al., 2015) . On the basis of these findings, inhibition of hepatic extracellular citrate uptake through SLC13A5 has been suggested as a potential therapeutic approach to treat metabolic disorders, such as type-2 diabetes and nonalcoholic or drug-induced steatohepatitis (Li et al., 2015; Neuschafer-Rube et al., 2014; Pesta et al., 2015; Rogers et al., 2015; Willmes et al., 2016) . Despite these initial encouraging findings however, the true therapeutic potential of SLC13A5 inhibition remains unclear. Interpretation of animal studies is complicated by marked model differences in physiology and SLC13A5 expression (Huard et al., 2015; Huard et al., 2016; Li et al., 2016; Pesta et al., 2015) .
Moreover, in contrast to rodent transporters that have a high affinity (<50 μM) but low capacity for M O L # 1 0 6 5 7 5 5 citrate, the human SLC13A5 has a much lower affinity (>500 μM) but high capacity (Gopal et al., 2015; Zwart et al., 2015) . Those major species differences in combination with the need for a better understanding of citrate levels and flux in human liver, complicates translational studies from rodents to humans and have led some to question the potential of SLC13A5 inhibitors for the treatment of diabetes and/or obesity (Li et al., 2016) .
Detailed pharmacological studies may help shed light on the therapeutic potential of SLC13A5. To date, only a limited number of SLC13A5 inhibitors have been identified. The recently discovered hydroxysuccinate inhibitors, PF-06649298 and PF-06761281, are perhaps the most potent and selective inhibitors described in the literature and may represent valuable tool compounds with which to explore the role of SLC13A5 in metabolic diseases. Initial findings suggest that both compounds exert only modest effects on plasma glucose levels, seemingly indicating that SLC13A5 plays only a limited role in the regulation of glucose metabolism. However, the mechanism of action of these first-generation tool compounds has not been studied in detail, leading to some ambiguity in the interpretation of in vivo proof-of-concept studies (Huard et al., 2015; Huard et al., 2016) . Although PF-06649298 has been described as a competitive substrate inhibitor, studies using an ester pro-drug of PF-06649298 in hepatocytes suggested that PF-06649298 could inhibit SLC13A5 through an intracellular-accessible binding site (Huard et al., 2015) . Moreover, in vivo administration of PF-06761281, described as a more potent inhibitor with suitable in vivo pharmacokinetic properties, paradoxically increased hepatic citrate concentrations, despite inhibiting uptake following an intra-arterial bolus of 14 C-citrate (Huard et al., 2016) . Taken together, these data suggest a more complex mechanism than competitive inhibition of the citrate transporter. (Gopal et al., 2015; Li et al., 2016; Zwart et al., 2015) , In the present study, we used a combination of 14 C-citrate uptake, membrane potential and electrophysiological assays to evaluate the pharmacology of PF-06649298 and PF-06761281 in more detail. Radiolabeled substrate transport is a convenient method to study transporter function but provides only very limited kinetic and mechanistic information and does not differentiate between substrate and non-substrate inhibitors. Since SLC13A5 is
6 a sodium-dependent transporter, with a Na + : substrate stoichiometry of 4:1 (Zwart et al., 2015) , we also took advantage of the electrogenic properties of this transporter, using both a newly developed membrane potential assay and whole-cell electrophysiology (Huard et al., 2015; Huard et al., 2016) . Both approaches allow discrimination between substrate and non-substrate inhibitors. Our results show that PF-06649298 and PF-06761281 are weak SLC13A5 substrates that block SLC13A5 in a predominantly allosteric, state-dependent manner, via an intracellular binding site. Our detailed mechanism of action studies may aid in the interpretation of the in vivo effects of these compounds at physiologically relevant citrate concentration and help further our understanding of the therapeutic potential of SLC13A5 inhibition.
Materials and Methods

Materials:
Culture media, serum, antibiotics, Zeocin, Blasticidin and buffers for cell culture were obtained from Thermo Fisher Scientific. Citric acid, sodium citrate, succinic acid and α-ketoglutarate were obtained from Sigma. PF-06649298 and PF-06761281 were synthesized according to previous reports (Huard et al., 2015; Huard et al., 2016 ).
14 C-citric acid was purchased from PerkinElmer (0.05 mCi/mL; 116.4 mCi/mmol).
Cell culture and stable cell line generation:
The cDNA for hSLC13A5 (NM_177550.4) was subcloned into pcDNA4-TO® (Invitrogen) using EcoRV and XbaI restriction sites. The HEK293-TRex cells were maintained at 37°C in a humidified 5% CO 2 incubator in culture medium (Dulbecco's Modified Eagle Medium (DMEM) supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% tetracycline-free fetal bovine serum). For the stable expression of human SLC13A5, cells were transfected with pcDNA4-TO/hSLC13A5 using Fugene according to the protocol of the manufacturer (Promega) and maintained for 2 weeks in selection medium containing 200 μg/mL Zeocin and 5 μg/mL Blasticidin. Antibiotic-resistant colonies were isolated and
screened individually in the 14 C-citrate uptake assay after overnight incubation with 1 μg/mL of tetracycline. Non-induced cells were used as a negative control.
14 C-citrate uptake assay:
HEK293TRex-TO/hSLC13A5 cells were induced overnight with 1 μg/mL tetracycline. Figure 1C ).
Membrane potential assay:
The effects of compounds on citrate-induced membrane depolarization were evaluated using membrane potential sensitive fluorescent dyes (FMP, Molecular Devices). Cells were split into poly-D-lysine coated black clear bottom 384-well plates (Corning BioCoat) in culture media with or without 1 μg/mL tetracycline overnight. 16-24h later, the medium was aspirated and 25ul of HBSS buffer with 2 mM 115 mM NaCl, 4 mM KCl, 10 mM HEPES, 5 mM glucose, 7.9 mM CaCl 2 , 3.7 mM MgCl 2 , 305 mosm, pH 7.4 (NaOH). Transporter currents were elicited at a holding potential of -60mV.
Results:
Citrate uptake:
In order to study the pharmacology of the citrate transporter, we developed an inducible HEK293TRex cell line stably expressing hSLC13A5. In this cell line, robust cell surface expression of the transporter could be demonstrated by immunofluorescence after overnight induction with tetracycline (Supplemental Consistent with inducible cell surface expression of SLC13A5, 14 C-citrate uptake increased in a linear fashion over 2-3 hours in induced cells and uptake was significantly greater than in non-induced cells at all time-points (Supplemental Figure 1C ). 14 C-citrate uptake into induced HEK293TRex-TO/hSLC13A5 cells was inhibited by succinate (IC 50 = 5.7 ± 1.3 mM) and α-ketoglutarate (IC 50 = 3.5 ± 1.2 mM) but not isocitrate (IC 50 > 10 mM) (data not shown) (average of 3 independent experiments ± S.E.M.), consistent with the known pharmacology of hSLC13A5 (Zwart et al., 2015) . Specific uptake was calculated from
1 0 the initial rate measured during the linear phase in the absence and presence of 50 mM α-ketoglutarate (Supplemental Figure 1D ). Although the apparent K m of hSLC13A5 for citrate using the standard Michaelis-Menten equation (Hill Slope h = 1) was approximately 575 ± 85 μM (average of 3 independent experiments ± S.E.M.) (Supplemental Figure 1D ), which is in good agreement with previous reports (Inoue et al., 2003; Pajor, 2014) , citrate transport through hSLC13A5 seemed biphasic and was better fitted using a cooperativity model ( Table 1 ). Interestingly, the potency of both compounds was increased in the presence of higher (20 μM 14 C-citrate + 230 μM cold citrate) citrate concentrations, to 0.58 ± 0.07 μM and 0.67 ± 0.09 μM respectively, suggesting an allosteric rather than a competitive mechanism of action. The potency of succinate at inhibiting citrate uptake was not significantly affected by the presence of higher citrate concentrations (not shown).
In order to assess their mechanism of action in more detail, we studied the effects of the inhibitors on citrate affinity and SLC13A5 maximal capacity. These experiments showed that PF-06649298 and PF-06761281 decreased the maximal capacity of the transporter ( Figure 1E and 1F) further suggesting an allosteric mechanism. Moreover, PF-06649298 and PF-06761281 also slightly but significantly and concentration-dependently increased the potency of citrate. For instance, PF-06649298 (5 μM) and PF-06761281 (2 μM) increased the potency of citrate (Table 2) , by approximately 3.8 and 6 fold, shifting citrate IC 50 from 745 ± 111 μM to 196 ± 3 μM and 112 ± 11 μM, respectively ( Figure 1C ). In contrast, succinate, a known SLC13A5 substrate, behaved as a competitive inhibitor, decreasing the affinity of the
transporter for citrate without affecting its maximal capacity (Supplemental Figure 2) . The citratedependent increase in potency of those compounds, as well as the slight increase in potency and decrease in maximal transport of citrate in presence of both PF-06649298 and PF-06761281 suggest that PF-06649298 and PF-06761281 behave as state-dependent or mixed non-competitive/un-competitive inhibitors (Krupka, 1983) . Moreover, in addition to slightly increasing citrate affinity, it is also noteworthy that PF-06649298 and PF-06761281 reduced the slope of the citrate concentration response curve, such that in presence of PF-06649298 and PF-06761281, citrate transport seemed better fitted by a one-site model (Michaelis-Menten Hill Slope = 1; Table 2 ).
Membrane depolarization:
To further probe the mechanism of PF-06649298 and PF-0676128, we exploited the electrogenic nature of SLC13A5 to develop a membrane potential-based transporter assay similar to those described for other electrogenic transporters (Jensen et al., 2004) . Importantly, unlike the 14 C-citrate uptake assay, membrane potential assays can differentiate between substrates and non-substrates and thus provide unique insight into transporter pharmacology. Using membrane potential sensitive fluorescent dyes, we found that citrate (EC 50 = 216 ± 13 μM) and succinate (EC 50 = 1018 ± 275 μM), depolarized induced but not noninduced HEK293TRex-TO/hSLC13A5 cells ( Figure 2A ). Isocitrate was inactive (not shown). PF-06649298 induced a depolarization that was only 26% of that induced by citrate at the top concentration tested (200μM) ( Figure 2C ). Higher concentrations could not be tested due to appearance of non-specific depolarization in non-induced cells. PF-06761281 appeared more potent with an EC 50 value of 4 ± 2 μM (Table 3) , but slightly less efficacious (~12%). EC 50 values are consistent with the low affinity of those compounds observed at low citrate concentrations ( Figure 1B ; Table 1 ). No depolarization was observed in non-induced cells at the concentrations shown in Figure 2C , confirming that the compound-induced depolarization was SLC13A5-mediated, and indicating that PF-06649298 and PF-06761281 were lowaffinity SLC13A5 substrates. Moreover, in contrast to citrate, compound-induced depolarization was 
Whole-cell patch-clamp:
We also used the whole-cell configuration of the patch-clamp technique to study the effects of PF- Figure 4A and 4D ). PF-06649298 appeared less potent, with 300μM PF-06649298 eliciting responses that were only ~25% of the 10mM citrate response ( Figure 4E ). Steady-state currents were very small, especially for PF-06761281 where they were often difficult to resolve in the background noise. Steady-state currents were larger for PF-06649298, which is consistent with the membrane potential results. EC 50 values for peak responses were approximately >300μM and 124μM for PF-06649298 and PF-06761281, respectively ( Figure 4F ). No responses were elicited by rapid application of DMSO (0.3%) or by either compound in non-induced cells (data not shown).
To study inhibitory activity, 10mM citrate-induced currents were elicited in the absence of PF-06649298
and PF-06761281 and again in the presence of PF-06649298 and PF-06761281 after ~5min preincubation with compounds. Pre-incubation with both compounds inhibited the 10mM citrate-induced current in a concentration dependent manner ( Figure 5C ). Inhibition by both compounds was also timedependent, with inhibition increasing during the application of 10mM citrate ( Figure 5AB ). For both compounds, IC 50 values were lower when measured against the steady state current at the end of the 10s citrate application (3μM and 0.28μM for PF-06649298 and PF-06761281, respectively) compared to the initial (peak) current (18μM and 1μM for PF-06649298 and PF-06761281, respectively. Figure 5C ).
Little/no reduction in the 10mM citrate response was observed in time matched control experiments with buffer or DMSO (0.1%). Compound effects were only slowly reversible with incomplete recovery even after prolonged washout (up to 30 minutes, not shown). As noted in the membrane potential assay, inhibition of SLC13A5 membrane currents was observed at concentrations of both compounds that were below the concentrations required for measurable substrate effects.
As weak substrates with low intrinsic membrane permeability, PF-06649298 and PF-06761281 have the potential to accumulate inside cells. Indeed, PF-06649298 has previously been reported to be concentrated by 29 fold inside HEK293 cells expressing hSLC13A5 (Huard et al., 2015) . We were interested therefore, to determine whether PF-06649298 and PF-06761281 could inhibit citrate-induced currents when delivered intracellularly. For these experiments, PF-06649298 and PF-06761281 were delivered by dialysis via the patch pipette. Currents were measured within a few seconds of membrane rupture (minimal compound exposure) and again after ~15 minutes of dialysis. Both compounds were able to inhibit citrate-induced responses when delivered in this way. Intracellular DMSO had no effect.
The time-dependent nature of the inhibition was qualitatively similar to that seen with extracellular delivery, with block developing rapidly after citrate addition ( Figure 6A , B). However, both compounds appeared less potent when applied to the inside rather than the outside of the cell ( Figure 6E ). Recovery from time-dependent block was measured using a two-pulse protocol with a variable recovery period ( Figure 6C, D) . Recovery was rapid for both compounds (tau = 2.7s and 2.0s for PF-06649298 and PF-06761281, respectively) indicative of low affinity in the absence of citrate ( Figure 6F ).
Discussion
PF-06649298 and PF-06761281 are inhibitors of the human citrate transporter, SLC13A5, but only limited information is available on the mechanism of transporter inhibition by these compounds. PF-06649298 has been described as a substrate and competitive inhibitor of SLC13A5 on the basis of its structural similarity to citrate and the observation that it accumulates inside cells expressing SLC13A5. It has also been speculated that PF-06649298 may occupy a second intracellular binding site (Huard et al., 2015) . The mechanism of action of PF-06761281 has not been studied at all, and additional studies are required to understand the basis of SLC13A5 inhibition by PF-06649298 and PF-06761281. In the present study, we addressed the mechanism of action of these compounds in detail, using a combination of 14 C-
citrate uptake, membrane potential and electrophysiological assays. We show that both compounds are weak SLC13A5 substrates that block SLC13A5 predominantly by an allosteric, state-dependent manner via an intracellular binding site.
We evaluated the substrate effects of PF-06649298 and PF-06761281 using two assays of transporter function. PF-06649298 and PF-06761281 exhibited clear substrate-like activity in both the membrane potential assay and in the electrophysiology studies. However, compounds appeared more potent, but less efficacious in the membrane potential assay compared to the electrophysiology. These differences likely represent differences in the kinetic resolution of the two assay formats. Due to the relatively slow compound addition/mixing and dye kinetics, the membrane potential assay essentially measures steadystate changes. In contrast, the direct nature of the electrophysiology assay, coupled with fast solution exchange captures rapid substrate responses. The membrane potential data demonstrates that both compounds are capable of inducing sustained transporter activity at relatively low concentrations. When applied rapidly in the electrophysiology assay, higher concentrations of both compounds were able to induce robust transporter currents. At the highest concentration tested, PF-06761281 was able to almost fully activate the transporter. In both formats, compound effects were transient (especially compound induced currents) and activity quickly declined after compound addition. The transient nature of the compound induced effects presumably represents rapid inhibition of the transporter by the transported compound (auto-inhibition).
In addition to being relatively low affinity substrates, our studies confirm that PF-06649298 and PF-06761281 are potent inhibitors of hSLC13A5 in presence of relatively high citrate concentrations (greater than physiological circulating citrate concentrations). However, our studies do not support the previous contention that PF-06649298 and PF-06761281 are competitive SLC13A5 inhibitors. Rather, our data are more consistent with a predominantly state-dependent or mixed non-competitive/un-competitive mechanism. This conclusion is supported by the following experimental evidence: 1) both compounds
reduce citrate V max and K m , 2) the inhibitory potency of both compounds is increased in the presence of higher citrate concentration 3) both compounds increase the inhibitory potency of citrate 4) both compounds are relative weak inhibitors of the initial current induced by citrate (suggesting low affinity inhibition in the absence of citrate) and 5) both show increased block with time after application of citrate and rapid dissociation on removal of citrate (suggesting higher affinity for an activated conformation of the transporter). In the electrophysiology studies we assume inhibition of the initial (or peak) citrateinduced current reflects affinity for the resting, or citrate unbound, outward facing state of the transporter and inhibition of the steady state current reflects affinity of the citrate bound, inward facing conformation.
If these assumptions are accurate, then both compounds exhibit modest selectivity for the citrate-bound state (~6 fold for PF-06649298 and 3.5 fold for PF-06761281). Although our studies show that the mechanism of inhibition is predominantly allosteric, the mechanism is clearly complex and dependent on both inhibitor and substrate concentrations. At high citrate concentrations the allosteric inhibitory mechanism clearly dominates. However, at lower, physiological citrate concentrations, inhibition is minimal and citrate affinity may be slightly increased.
All available data suggest that the location of the allosteric inhibitory binding site is accessible from intracellular side of the membrane. An intracellular location of the inhibitory binding site for PF-06649298 was first suggested by studies using an ester pro-drug (Huard et al., 2015) . The ester prodrug was able to deliver active PF-06649298 only to the inside of human hepatocytes but nevertheless retained the ability to inhibit citrate transport. Our results showing that the compounds can block SLC13A5 when applied to either side of the membrane is also entirely consistent with an intracellular location. Previous studies indicate that the drug concentrations used in the present study are achievable in-vivo and therefore, therapeutically/physiologically relevant. Thus, PF-06649298 at 250mg/kg p.o. is reported to reach free liver concentrations of ~100μM (Huard et al., 2015) . Likewise, infusions of PF-06761281 generate liver concentrations of >10μM in mice (Huard et al., 2016) . Our detailed mechanism of action studies therefore, may be of value in interpreting the in vivo effects of these compounds. As allosteric state-dependent modulators, the inhibitory potency of both compounds is highly dependent on the ambient citrate concentration. Importantly, by preferring citrate-bound, inward facing transporters, PF-06649298 and PF-06761281 are least effective when ambient citrate concentrations are in the
1 8 physiological range (~100uM, (Gopal et al., 2015; Li et al., 2016) ). The extent to which these compounds are capable of inhibiting hepatic citrate under normal physiological conditions is therefore unclear.
Interpreting the effects of PF-06649298 and PF-06761281 may be further complicated by the known species dependent pharmacology and transport capacity of SLC13A5 (Gopal et al., 2015; Inoue et al., 2003; Zwart et al., 2015) and additional mechanistic studies with mouse SLC13A5 as well as other dicarboxylate transporters are needed. In the absence of a more complete understanding of the pharmacology of PF-06649298 and PF-06761281, in vivo studies with these compounds should be interpreted with a degree of caution.
In conclusion, to assess the complex pharmacology of the human SLC13A5 transporter and of two of its recently identified inhibitors, PF-06649298 and PF-06761281, we used radioactive citrate uptake in combination with a membrane potential assay and electrophysiology that allowed discrimination between non-substrate and substrate activity. We characterized PF-06649298 and PF-06761281 as potent statedependent inhibitors with relatively weak substrate activity, that most likely bind to an intracellularaccessible site once transported inside the cells. Our detailed mechanistic studies may aid in the interpretation of the in vivo effects of these compounds at physiologically relevant citrate concentration and help further our understanding of the therapeutic potential of SLC13A5 inhibition. 
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: Symbols represent the mean ± S.E.M for n = 3 independent experiments. Corresponding EC50 and IC50 values are represented in Table 3 (averages ± S.E.M. from 3 independent experiments). (50μM) and PF-06761281 (50μM) were included in the pipette solution and 10mM citrate-induced currents were elicited every 60s for 15min, starting immediately after break-in (~0min). Citrate was applied for 10s to cells held at -60mV. Block developed over time (with dialysis). At ~15 min, block for both was modest at the start of the 10s citrate application but increased during the 10s citrate application.
Percent inibition by each compound was calculated at the start (peak) and the end of the citrate response Representative recordings are shown in C-D. Percent recovery was plotted against recovery interval in F.
Recovery from block occurs rapidly after removal of citrate for both compounds. Tau values were 2.7s and 2.0s for PF-06649298 and PF-06761281, respectively.
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